Trials / Terminated
TerminatedNCT04614987
Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 17 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators propose that immune effector cell-associated neurotoxicity syndrome (ICANS) is predicated upon the early loss of blood brain barrier (BBB) integrity with subsequent monocyte infiltration leading to cross-activation of native glial cells. Glial overstimulation leads to neuroinflammation, synaptic dysfunction, and ultimately neuronal injury.
Conditions
Timeline
- Start date
- 2021-02-25
- Primary completion
- 2023-09-13
- Completion
- 2023-09-13
- First posted
- 2020-11-04
- Last updated
- 2025-05-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04614987. Inclusion in this directory is not an endorsement.